araag2/HINT huggingface dataset:
Clinical trial NCT01718379 (phase 2, status: completed)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: lenalidomide, epoetin beta
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

        MDS defined as

          -  Low or int-1 IPSS score

          -  Documented absence of chromosome 5 abnormality (del(5q) or -5 karyotype)

          -  De novo MDS, excluding therapy-related MDS AND

          -  Transfusion dependance (requirement of at least 4 units of RBC transfusions every 8
             weeks )

          -  Resistance or loss of response to a previous treatment with Epoetin alpha/beta (at
             least 60,000 Units/w) or Darbepoetin (at least 250 µg/w), for at least 12 weeks

          -  Ineligibility for allogeneic stem cell transplantation or intensive chemotherapy
             during the next 12 months

          -  ECOG performance status ≤ 2

          -  Age ≥ 18 years

          -  Life expectancy ≥ 3 months

          -  Adequate liver function (transaminases serum levels ≤ 3N)

          -  Adequate renal function (calculate creatinine clearance > 50 ml/min)

          -  Female subjects of chilbearing potential* must :

        Agree to use effective contraception without interruption throughout the study and for at
        least 4 weeks after the end of treatment

        • Men must: Agree to not conceive during the treatment and to use effective contraception
        during the treatment period (including periods of dose reduction or temporary suspension)
        and during one week after end of treatment if their partner is of childbearing potential.

        Exclusion Criteria:

          -  Active serious infection not controlled by oral or intravenous antibiotics

          -  Platelets less than 50 G/L

          -  Prior history of deep vein thrombosis or pulmonary embolism

          -  Previous treatment by Thalidomide

          -  Treatment with any investigational antileukemic agent or chemotherapy at least 6 weeks
             prior to study entry and lack of full recovery from side effects due to prior therapy
             independent of when that therapy were given

          -  Rapidely progressive disease with copromised organ function judged to be
             life-threatening by the Investigator

          -  Pregnant or lactating female

          -  Known human immunodeficiency virus (HIV) infection

          -  Known active hepatitis B and/or C virus infection

          -  Hypersensitivity or intolerance to Lenalidomide or any of the excipients

          -  Hypersensitivity to Epoetin beta or any of the excipients

          -  Uncontrolled arterial hypertension

          -  Any history of malignancy (other than myelodysplastic syndrome) unless the patient has
             remained disease free for more than 5 years
Clinical trial NCT00143273 (phase 2, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: lasofoxifene, placebo, lasofoxifene, lasofoxifene
SMILES: [H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1, [H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  postmenopausal Asian women with osteoporosis defined by low BMD

        Exclusion Criteria:

          -  Metabolic bone disease, use of other osteoporosis drugs or drugs interering with
             normal bone metabolism
Clinical trial NCT01037881 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: leo 29102, elidel®
SMILES: [H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of atopic dermatitis defined according to Hanifin and Rajka

          -  IGA assessment scored as mild (2) to moderate (3) atopic dermatitis

          -  Treatment lesions located on the trunk and limbs

          -  Treatment lesions involving 3% to 10% of the total body surface area

          -  Patients of either gender between 18 years and 65 years of age

        Exclusion Criteria:

          -  Systemic treatment with immunosuppressive drugs or corticosteroids within 6 weeks
             prior to randomisation

          -  Topical treatment with immunomodulators (pimecrolimus, tacrolimus) within 2 weeks
             prior to randomisation

          -  Topical treatment with corticosteroids from WHO groups II, III or IV within 1 week
             prior to randomisation

          -  Use of topical or systemic antibiotics within 2 weeks prior to randomisation

          -  PUVA or UVB therapy within 4 weeks prior to randomisation

          -  Clinical infection (viral, fungal or bacterial) on the treatment area

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Patients with history of an immunocompromised disease (e.g., lymphoma, HIV,
             Wiskott-Aldrich Syndrome)

          -  Patients with concomitant serious disease (e.g., cancer) which might affect the AD
             treatment in this trial

          -  Females who are pregnant or are breast feeding

          -  Females intending to temporarily or permanently stop their hormonal contraceptive
             regime during and up to one month post study termination visit
Clinical trial NCT01566773 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: pt001 mdi, tiotropium bromide, pt001 placebo mdi
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70

          -  A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
Clinical trial NCT01072695 (phase 2, status: completed)
Conditions: hcv infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: gs-9256, gs-9190, ribavirin, peginterferon alfa-2a
SMILES: COC1=C(Cl)C2=NC(=CC(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCCC[C@@H]3C[C@]3(NC4=O)P(O)(=O)CC3=C(F)C=CC=C3F)NC(=O)OC3CCCC3)=C2C=C1)C1=CSC(NC(C)C)=N1, FC1=CC=CC=C1C1=NC2=CN(CC3=CC=C(N=N3)C3=CC=C(C=C3C(F)(F)F)C(F)(F)F)C=CC2=N1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects, ages 18-70

          -  Willing able to provide informed consent

          -  BMI between 18 and 36 kg/m2 (inclusive)

          -  Chronic HCV infection, genotype 1

          -  HCV RNA >/= 3 log, but < 7.2 log10 IU/ml at screen

          -  Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis

          -  HCV treatment naïve with imminent plans to start treatment with PEG/RIBA

          -  QTcF </= 450 msec at screen

          -  ALT, AST, GGT < 5 X ULN at the screening visit

          -  Creatinine clearance >= 50 mL/min

          -  Absolute neutrophil count >= 1500/mm3

          -  Hemoglobin >/= 12 g/dL (female), >/= 13 g/dL (male)

          -  Males agree to use of effective contraception and refrain from sperm donation

          -  Able to comply with dosing instructions and study visits

          -  Of generally good health

        Exclusion Criteria:

          -  Females of child-bearing potential or males with female partners who are pregnant or
             planning to become pregnant

          -  Infection with other HCV genotype or multiple HCV genotypes

          -  Poorly controlled diabetes

          -  Hemoglobinopathy or known retinal disease

          -  History of sarcoidosis or invasive malignancy

          -  Untreated or significant psychiatric illness

          -  Co-infection with hepatitis B virus or human immunodeficiency virus

          -  Chronic use of systemic immunosuppressive agents

          -  Autoimmune disorders

          -  Severe COPD

          -  History of significant cardiac disease

          -  Known cirrhosis

          -  Non-HCV chronic liver disease

          -  Transplantation

          -  Suspicion of hepatocellular carcinoma

          -  Bilirubin above the normal range or Gilbert's syndrome

          -  Decompensated liver disease

          -  Clinically significant illness

          -  GI disease that could interfere with absorption

          -  Acute porphyria

          -  Current excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4
             drinks/day for males or current binge drinking

          -  Positive urine drug screen

          -  History of difficult blood collection

          -  Significant recent blood loss

          -  Prohibited medications, including H2 antagonists, investigational agents

          -  Restricted fruits, fruit juices

          -  Hypersensitivity
Clinical trial NCT00041327 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine
SMILES: OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed HTLV-1-associated adult T-cell
             leukemia/lymphoma (ATLL)

               -  Previously treated ATLL allowed

          -  CD3-positive

          -  Documented HTLV-1 infection by serologic assay (ELISA, Western blot)

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 50-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3*

          -  Platelet count greater than 75,000/mm^3* NOTE: *Unless cytopenia is secondary to ATLL

        Hepatic:

          -  Transaminase less than 7 times upper limit of normal

          -  Bilirubin less than 2.0 mg/dL (unless secondary to hepatic infiltration with lymphoma
             or isolated indirect hyperbilirubinemia associated with indinavir)

        Renal:

          -  Creatinine less than 2.0 mg/dL (unless due to lymphoma)

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             completion

          -  No active opportunistic infection requiring acute therapy

          -  No untreated thyroid disease

          -  No autoimmune disease

          -  No uncontrolled significant psychiatric disease

          -  No other concurrent malignancy except carcinoma in situ of the cervix or
             non-metastatic nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 24 hours since prior hematologic growth factors

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  Concurrent chronic therapy with potentially myelosuppressive agents allowed

          -  Other concurrent antiretroviral therapy for HIV, hepatitis B, or hepatitis C infection
             (or other indication) allowed at investigator's discretion for patients receiving
             therapy prior to study initiation
Clinical trial NCT00090064 (phase 2, status: completed)
Conditions: posttraumatic stress disorder
ICD codes: F43.10, F43.11, F43.12
Drugs: 3,4-methylenedioxymethamphetamine (mdma), lactose (placebo
SMILES: CNC(C)CC1=CC2=C(OCO2)C=C1, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Be diagnosed with chronic PTSD, duration of 5 years or longer resulting from traumatic
             experience during military service or a victim of crime;

          -  Have a CAPS score showing moderate to severe PTSD symptoms;

               1. Have had at least one unsuccessful attempt at treatment for PTSD either with talk
                  therapy or with drugs, or discontinuing treatment because of inability to
                  tolerate psychotherapy or drug therapy.

               2. Are at least 18 years old;

          -  Must be generally healthy;

          -  Must sign a medical release for the investigators to communicate directly with their
             therapist and doctors;

          -  Are willing to refrain from taking any psychiatric medications during the study
             period;

          -  Willing to follow restrictions and guidelines concerning consumption of food,
             beverages, and nicotine the night before and just prior to each experimental session;

          -  Willing to remain overnight at the study site;

          -  Agree to have transportation other than driving themselves home or to where they are
             staying after the integrative session on the day after the MDMA session;

          -  are willing to be contacted via telephone for all necessary telephone contacts;

          -  Must have a negative pregnancy test if able to bear children, and agree to use an
             effective form of birth control;

          -  must provide a contact in the event of a participant becoming suicidal;

          -  Are proficient in speaking and reading English;

          -  agree to have all clinic visit sessions recorded to audio and video

          -  Agree not to participate in any other interventional clinical trials during the
             duration of this study.

        Exclusion Criteria:

          -  Are pregnant or nursing, or if a woman who can have children, those who are not
             practicing an effective means of birth control;

          -  Weigh less than 50 kg;

          -  Are abusing illegal drugs;

          -  Are unable to give adequate informed consent;

          -  Upon review of past and current drugs/medication must not be on or have taken a
             medication that is exclusionary.

          -  Upon review of medical or psychiatric history must not have any current or past
             diagnosis that would be considered a risk to participation in the study
Clinical trial NCT01998919 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib [tarceva], placebo, gemcitabine, cisplatin, carboplatin
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  histologically documented advanced or recurrent stage IIIB or IV non-small cell lung
             cancer;

          -  measurable disease;

          -  no previous chemotherapy for non-small cell lung cancer.

        Exclusion Criteria:

          -  unstable systemic disease;

          -  any other malignancies in the last 5 years.
Clinical trial NCT00755534 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan, capecitabine, cetuximab, oxaliplatin
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic colorectal cancer

          -  Measurable or evaluable disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST)

          -  ECOG performance status ≤ 2

          -  Age 18 - 72 years

          -  Patients who have had a CR, PR or SD after 1st line therapy based on
             Irinotecan+Bevacizumab

          -  Paraffin block from the primary tumor in order to perform tha mutational analysis of
             the KRAS gene

          -  Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit,
             ALP ≤ 2.5 upper normal limit),renal (Creatinine ≤ 1.5 upper normal limit) and bone
             marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function

          -  Patients must be able to understand the nature of this study

          -  Written informed consent

        Exclusion Criteria:

          -  Presence of central nervous system or brain metastases

          -  Pregnant or lactating woman

          -  Life expectancy < 3 months

          -  Previous radiotherapy within the last 4 weeks or > 25% of bone marrow or in the field
             where the treatment target is located

          -  Peripheral neuropathy grade ≥2

          -  Known hypersensitivity to Erbitux

          -  Metastatic infiltration of the liver >50%

          -  Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or
             total colectomy

          -  Active infection

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer

          -  Psychiatric illness or social situation that would preclude study compliance
Clinical trial NCT01309945 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: duloxetine, placebo matching with bms-820836, bms-820836, duloxetine, placebo matching with duloxetine
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be able to understand the nature of the study, agree to comply with the
             prescribed dosage regimens, report for regularly scheduled office visits, and
             communicate to study personnel about adverse events and concomitant medication use.

          -  Patients with a diagnosis of Major Depressive Disorder, currently experiencing a Major
             Depressive Episode, as defined by Diagnostic and Statistical Manual of Mental
             Disorders- Fourth Edition Text Revision(DSM IV TR) criteria. The current depressive
             episode must be > 8 weeks in duration and < 3 years duration.

          -  In the current Major Depressive Disorder (MDD) episode, patients should report a
             history of inadequate response to 1 - 3 adequate trials of antidepressant treatment.

          -  Patients must have a 17-item Hamilton Depression Rating Scale (HAM-D17) total score
             =>18 at Screening.

        Exclusion Criteria:

          -  Patients who report an inadequate response (less than 50% reduction in depressive
             symptom severity) to more than three adequate trials of antidepressant treatments
             during the current depressive episode.

          -  Patients who have failed duloxetine at an adequate dose and for an adequate duration
             in their current episode unless in the judgment of the investigator, the patient could
             benefit from the treatment with this medication.

          -  Patients whose only inadequate response to an antidepressant in the current Major
             Depressive Episode (MDE) is to an Serotonin norepinephrine reuptake inhibitors (SNRI)
             (duloxetine, venlafaxine, desvenlafaxine or milnacipran).
Clinical trial NCT00097929 (phase 2, status: completed)
Conditions: b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: mk0683, vorinostat, suberoylanilide hydroxamic acid (saha) / duration of treatment 6 months
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).

          -  Stable disease or better for at least 3 months on most recent treatment

          -  Have not received any chemotherapy, radiation therapy, major surgery, or any other
             investigational therapy for at least 4 weeks prior to entry in this study

          -  Adequate blood testing, liver, and kidney function as required by the study.

          -  Eligible subjects will allow tissue samples to be examined and stored.

        Exclusion Criteria:

          -  Patient has been treated with other investigational agents with a similar anti-tumor
             mechanism.

          -  Patient should not have failed more than 3 prior treatment regimens.